Jun 2026 (Q2 FY26) — Aug 5, 2026
Coherus Oncology Q2 FY26 — Pipeline Data Maturation and LOQTORZI Growth
Read the full callCoherus Oncology (CHRS) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Coherus Oncology earnings: last reported Wed, 5 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 14.3 | +39.5% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -226.0 | +217.6 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -20.6 | −106.9% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$0.96 −3.03% · −$0.03
Performance −41.8% 1Y
1Y: $1.65 on 17 Oct 2025 → $0.96. High $2.51 (27 Jan 2026), low $0.96 (19 Oct 2026).
- Previous close
- $0.99
- 52-week range
- $0.96 – $2.51
- One year
- −46.37%
Overview
- Symbol
- CHRS
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Coherus Oncology earnings calls (CHRS)
Financials
What the filings say
Net profit, year on year: −107% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 6 | 54 | 8 | 10 | 12 | 13 | 12 | 14 |
| Expenses | 53 | 96 | 53 | 56 | 56 | 59 | 48 | 47 |
| Operating profit | -47 | -42 | -45 | -45 | -44 | -46 | -36 | -32 |
| Operating margin | −774.2% | −78.0% | −597.9% | −443.6% | −383.1% | −359.9% | −293.7% | −226.0% |
| Interest | 3 | 5 | 2 | 2 | 2 | 2 | 2 | 2 |
| Profit before tax | -48 | -51 | -47 | -45 | -45 | -46 | -37 | -33 |
| Net profit | -11 | -51 | -57 | 298 | -36 | -38 | -38 | -21 |
| EPS ($ per share) | -0.09 | — | -0.49 | 2.57 | -0.31 | — | -0.28 | -0.13 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -985 | -895 | -763 | -1,050 | -1,342 | -1,579 | -1,551 | -1,383 |
| Total liabilities | 138 | 304 | 561 | 582 | 618 | 823 | 581 | 197 |
| Fixed assets | 7 | 6 | 10 | 8 | 9 | 5 | 3 | 1 |
| Investments | 0 | 0 | — | — | 128 | 15 | — | 83 |
| Total assets | 99 | 409 | 842 | 679 | 481 | 630 | 449 | 258 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -159 | 28 | 154 | -37 | -241 | -175 | -20 | -139 |
| Cash from investing | -1 | -13 | -14 | -138 | -167 | 145 | 230 | 375 |
| Cash from financing | 105 | 89 | 224 | 52 | 54 | 70 | -187 | -274 |
| Net cash flow | -55 | 105 | 364 | -124 | -354 | 39 | 23 | -37 |
| Capital expenditure | -1 | -2 | -7 | -1 | -2 | -0 | — | — |
| Free cash flow | -160 | 27 | 147 | -39 | -243 | -175 | — | — |
Insider filings
11 filings between Jan 20, 2026 and Jun 5, 2026.
Open market
decisions to buy or sellNobody bought or sold CHRS on the open market in this window. The filings below are 9 awards and 2 tax withholdings.
Compensation
not trading decisions- 9
- Award — granted as compensation
- 2
- Tax withheld — shares kept back by the company to cover tax
Latest filings (19)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Jun 5, 2026 | Newcomer Lee Nisley Director | Award | 30,000 | $0 |
| Jun 5, 2026 | Karachun Rita A Director | Award | 30,000 | $0 |
| Jun 5, 2026 | Satvat Ali J. Director | Award | 30,000 | $0 |
| Jun 5, 2026 | Newton Charles W. Director | Award | 30,000 | $0 |
| Jun 5, 2026 | Wahlstrom Mats Director | Award | 30,000 | $0 |
| Jun 5, 2026 | O'Donnell-Tormey Jill Director | Award | 30,000 | $0 |
| Jun 5, 2026 | Ryan Michael Lee Director | Award | 30,000 | $0 |
| Jan 23, 2026 | Lanfear Dennis M President & CEO | Award | 375,000 | $0 |
| Jan 22, 2026 | McMichael Bryan J Chief Financial Officer | Award | 112,500 | $0 |
| Jan 20, 2026 | Lanfear Dennis M President & CEO | Tax withheld | 11,839 | $18.4K |
| Jan 20, 2026 | McMichael Bryan J Chief Financial Officer | Tax withheld | 1,715 | $2.7K |
| May 23, 2025 | Wahlstrom Mats Director | Sale | 99,988 | $73.9K |
| Jan 20, 2025 | Lanfear Dennis M President & CEO | Tax withheld | 11,810 | $16.4K |
| Jan 20, 2025 | Reider Paul Chief Commercial Officer | Tax withheld | 4,858 | $6.8K |
| Jan 20, 2025 | McMichael Bryan J Chief Financial Officer | Tax withheld | 1,711 | $2.4K |
| Jan 7, 2025 | McMichael Bryan J Chief Financial Officer | Tax withheld | 1,711 | $2.7K |
| Jan 4, 2025 | Reider Paul Chief Commercial Officer | Tax withheld | 2,277 | $3.8K |
| Jan 4, 2025 | Lanfear Dennis M President & CEO | Tax withheld | 11,810 | $19.6K |
| Dec 13, 2024 | Reider Paul Chief Commercial Officer | Tax withheld | 2,073 | $3.3K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Coherus Oncology, Inc.
Free account. Everything above stays public.
Write why you follow Coherus Oncology, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading